{"protocolSection": {"identificationModule": {"nctId": "NCT01230307", "orgStudyIdInfo": {"id": "VitD3"}, "organization": {"fullName": "University of Michigan", "class": "OTHER"}, "briefTitle": "Vitamin D Supplementation for Treatment of Heart Failure", "officialTitle": "D suppLementation In HearT FaiLure (DELIGHTFUL)", "acronym": "DELIGHTFUL"}, "statusModule": {"statusVerifiedDate": "2016-09", "overallStatus": "TERMINATED", "whyStopped": "Unable to recruit sufficient number of patients.", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-10"}, "primaryCompletionDateStruct": {"date": "2014-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-10-27", "studyFirstSubmitQcDate": "2010-10-28", "studyFirstPostDateStruct": {"date": "2010-10-29", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-09-28", "resultsFirstSubmitQcDate": "2016-09-28", "resultsFirstPostDateStruct": {"date": "2016-11-18", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-09-28", "lastUpdatePostDateStruct": {"date": "2016-11-18", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Barry E. Bleske", "investigatorTitle": "Associate Professor", "investigatorAffiliation": "University of Michigan"}, "leadSponsor": {"name": "University of Michigan", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The central objective of this proposal is to establish that vitamin D supplementation in heart failure patients with low vitamin D levels will have improved outcomes compared to placebo. In addition the investigators will also evaluate the role of genetics in regard to vitamin D and heart failure. The investigators will be evaluating what is currently a novel approach of identifying patients with low vitamin D and treating this low vitamin D level. The investigators will be able to evaluate the importance of vitamin D supplementation in these patients and the role of genetics on our defined outcomes.", "detailedDescription": "Primary Objective To determine how rapid vitamin D supplementation affects biomarkers and submaximal exercise capacity in systolic HF patients with low vitamin D status.\n\nWorking Hypothesis 1: HF patients when supplemented with vitamin D for 6 months will have lower measures of inflammation and extracellular-matrix remodeling compared with placebo.\n\nWorking Hypothesis 2: HF patients when supplemented with vitamin D for 6 months will have longer 6-minute walk length compared with placebo.\n\nSecondary Objectives To establish a relationship between the CYP2R1 variant and surrogate markers in systolic HF patients.\n\nWorking Hypothesis 3: HF patients with the CYP2R1 G allele will have higher measures of inflammation and extracellular-matrix remodeling compared to AA subjects. This relationship will also be seen in subjects with the CYP2R1 TagSNP variants.\n\nWorking Hypothesis 4: HF patients with CYP2R1 variant alleles will have shorter 6-minute walk length compared to subjects without these variants.\n\nTo genotype HF subjects for the VDR variants and additional tag SNPs, to ascertain the relationship between VDR genetic variation and surrogate markers in systolic HF patients.\n\nWorking Hypothesis 5: HF patients with VDR variants will have greater measures of inflammation and extracellular-matrix remodeling compared to subjects without VDR variants.\n\nWorking Hypothesis 6: HF patients with VDR variants will have a shorter 6-minute walk length compared to subjects without these variants."}, "conditionsModule": {"conditions": ["Heart Failure"], "keywords": ["Vitamin D", "Systolic failure", "Genomics", "Biomarkers", "Exercise", "Quality of Life"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER"]}}, "enrollmentInfo": {"count": 28, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Vitamin D", "type": "ACTIVE_COMPARATOR", "description": "Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months", "interventionNames": ["Drug: Vitamin D3"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "A placebo loading dose will be given followed by two placebo tablets daily for 6 months.", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Vitamin D3", "description": "Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months", "armGroupLabels": ["Vitamin D"], "otherNames": ["cholecalciferol"]}, {"type": "DRUG", "name": "Placebo", "description": "A placebo loading dose will be given followed by 2 placebo tablets daily for 6 months.", "armGroupLabels": ["Placebo"], "otherNames": ["Sugar Pill"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Biomarkers", "description": "Biomarkers - C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-a (TNF-a), propeptide procollagen type I, plasma procollagen III, matrix metalloproteinase 2 (MMP-2), MMP-9 and tissue inhibitor of matrix metalloproteinases-1 (TIMP-1).", "timeFrame": "6 months"}], "secondaryOutcomes": [{"measure": "Exercise Capacity Measured by 6 Minute Walk Test", "timeFrame": "6 months"}, {"measure": "Quality of Life Measured by Kansas City Cardiomyopathy Questionnaire", "description": "Kansas City Cardiomyopathy Questionnaire for quality of life is measured on a scale of 0 - 100, with 100 being best.", "timeFrame": "6 months"}, {"measure": "Vitamin D Genomics", "description": "Genotyped for the restricted fragment length polymorphism at the BsmI site. In addition CYP2R1, CYP27B1, CYP24 will also be genotyped.", "timeFrame": "Baseline"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* HF patients with LV systolic dysfunction of ischemic or non-ischemic origin and an LVEF \\<40% using nuclear ventriculography or echocardiography within the last 6 months.\n* Attempts should have been made at optimizing medical therapy and the participant should be stable on these medications for at least 3 months.\n* Patients with a 25(OH)D level between 10-25 ng/ml\n\nExclusion Criteria:\n\n* Inability to give informed consent\n* Patients with sarcoidosis or other granulomatous disease that can alter vitamin D metabolism\n* Patients with primary valvular HF, hypertrophic cardiomyopathy, and drug-induced HF\n* Renal dysfunction defined as serum creatinine \\> 2.5 mg/dl\n* Pregnant women\n* Patients \\<18 years of age\n* Patients on vitamin D supplementation", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Barry E. Bleske, Pharm. D.", "affiliation": "University of Michigan", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University of Michigan Medical Center", "city": "Ann Arbor", "state": "Michigan", "zip": "48109", "country": "United States", "geoPoint": {"lat": 42.27756, "lon": -83.74088}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "16 consented participants were not randomized due to screen fails.", "groups": [{"id": "FG000", "title": "Vitamin D", "description": "Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months\n\nVitamin D3: Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months"}, {"id": "FG001", "title": "Placebo", "description": "A placebo loading dose will be given followed by two placebo tablets daily for 6 months.\n\nPlacebo: A placebo loading dose will be given followed by 2 placebo tablets daily for 6 months."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "LVAD Placement", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Vitamin D", "description": "Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months\n\nVitamin D3: Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months"}, {"id": "BG001", "title": "Placebo", "description": "A placebo loading dose will be given followed by two placebo tablets daily for 6 months.\n\nPlacebo: A placebo loading dose will be given followed by 2 placebo tablets daily for 6 months."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "12"}]}], "measures": [{"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "46 - 78 Years", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "12"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "2"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "10"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "10"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Baseline Vit D level (ng/mL)", "description": "Baseline Vit D level nanograms per milliliter of blood.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "ng/mL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "16.3", "spread": "5"}, {"groupId": "BG001", "value": "19.6", "spread": "3"}, {"groupId": "BG002", "value": "17.8", "spread": "4"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Biomarkers", "description": "Biomarkers - C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-a (TNF-a), propeptide procollagen type I, plasma procollagen III, matrix metalloproteinase 2 (MMP-2), MMP-9 and tissue inhibitor of matrix metalloproteinases-1 (TIMP-1).", "populationDescription": "Because enrollment was less than 30% of original goal (6 vs 4 subjects) and therefore would not have scientific validity and would be a waste of financial resources, this outcome was not analyzed.", "reportingStatus": "POSTED", "timeFrame": "6 months", "groups": [{"id": "OG000", "title": "Vitamin D", "description": "Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months\n\nVitamin D3: Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months"}, {"id": "OG001", "title": "Placebo", "description": "A placebo loading dose will be given followed by two placebo tablets daily for 6 months.\n\nPlacebo: A placebo loading dose will be given followed by 2 placebo tablets daily for 6 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Exercise Capacity Measured by 6 Minute Walk Test", "populationDescription": "Because enrollment was less than 30% of original goal (6 vs 4 patients) and therefore would not have scientific validity and no conclusions could be determined, this outcome was not analyzed.", "reportingStatus": "POSTED", "timeFrame": "6 months", "groups": [{"id": "OG000", "title": "Vitamin D", "description": "Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months\n\nVitamin D3: Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months"}, {"id": "OG001", "title": "Placebo", "description": "A placebo loading dose will be given followed by two placebo tablets daily for 6 months.\n\nPlacebo: A placebo loading dose will be given followed by 2 placebo tablets daily for 6 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Quality of Life Measured by Kansas City Cardiomyopathy Questionnaire", "description": "Kansas City Cardiomyopathy Questionnaire for quality of life is measured on a scale of 0 - 100, with 100 being best.", "populationDescription": "Because enrollment was less than 30% of original goal (6 vs 4 patients) and therefore would not have scientific validity and no conclusions could be determined, this outcome was not analyzed.", "reportingStatus": "POSTED", "timeFrame": "6 months", "groups": [{"id": "OG000", "title": "Vitamin D", "description": "Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months\n\nVitamin D3: Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months"}, {"id": "OG001", "title": "Placebo", "description": "A placebo loading dose will be given followed by two placebo tablets daily for 6 months.\n\nPlacebo: A placebo loading dose will be given followed by 2 placebo tablets daily for 6 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Vitamin D Genomics", "description": "Genotyped for the restricted fragment length polymorphism at the BsmI site. In addition CYP2R1, CYP27B1, CYP24 will also be genotyped.", "populationDescription": "Because enrollment was less than 30% of original goal (6 vs 4 patients) and therefore would not have scientific validity, in addition there is significant time and costs associated with this measurement which would result in data that would lead to no conclusions, this outcome was not analyzed.", "reportingStatus": "POSTED", "timeFrame": "Baseline", "groups": [{"id": "OG000", "title": "Vitamin D", "description": "Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months\n\nVitamin D3: Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months"}, {"id": "OG001", "title": "Placebo", "description": "A placebo loading dose will be given followed by two placebo tablets daily for 6 months.\n\nPlacebo: A placebo loading dose will be given followed by 2 placebo tablets daily for 6 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "6 months", "eventGroups": [{"id": "EG000", "title": "Vitamin D", "description": "Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months\n\nVitamin D3: Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months", "seriousNumAffected": 2, "seriousNumAtRisk": 6, "otherNumAffected": 0, "otherNumAtRisk": 6}, {"id": "EG001", "title": "Placebo", "description": "A placebo loading dose will be given followed by two placebo tablets daily for 6 months.\n\nPlacebo: A placebo loading dose will be given followed by 2 placebo tablets daily for 6 months.", "seriousNumAffected": 0, "seriousNumAtRisk": 6, "otherNumAffected": 0, "otherNumAtRisk": 6}], "seriousEvents": [{"term": "GI bleed", "organSystem": "Gastrointestinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}]}, {"term": "syncope due to hypokalemia", "organSystem": "Nervous system disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Only a fraction of the original goal of enrollment was met. Therefore, analysis of comparative results was not done. No conclusions of any kind can be made from analyzing the data with the number of patients completing the trial (6 vs 4 patients)."}, "certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Barry Bleske", "organization": "University of Michigan", "email": "bbleske@umich.edu", "phone": "734-763-3232"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M27583", "name": "Systolic Murmurs", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "T6034", "name": "Quality of Life", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "BXM", "name": "Behaviors and Mental Disorders"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000014807", "term": "Vitamin D"}, {"id": "D000002762", "term": "Cholecalciferol"}], "ancestors": [{"id": "D000014815", "term": "Vitamins"}, {"id": "D000018977", "term": "Micronutrients"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000050071", "term": "Bone Density Conservation Agents"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}], "browseLeaves": [{"id": "M17550", "name": "Vitamin D", "asFound": "Acid", "relevance": "HIGH"}, {"id": "M6003", "name": "Cholecalciferol", "asFound": "Schedule", "relevance": "HIGH"}, {"id": "M17558", "name": "Vitamins", "relevance": "LOW"}, {"id": "M21009", "name": "Micronutrients", "relevance": "LOW"}, {"id": "M16885", "name": "Trace Elements", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "T479", "name": "Vitamin D3", "asFound": "Diabetic", "relevance": "HIGH"}, {"id": "T442", "name": "Cholecalciferol", "asFound": "Schedule", "relevance": "HIGH"}, {"id": "T440", "name": "Calciferol", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "Micro", "name": "Micronutrients"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Vi", "name": "Vitamins"}]}}, "hasResults": true}